Plasma α-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 4, 2008, Pages 1470-1475

  Joseph, Gowsini ^a   Tarnow, Lise ^c   Astrup, Anne Sofie ^c   Hansen, Troels Krarup ^a   Parving, Hans Henrik ^b,c   Flyvbjerg, Allan ^a   Frystyk, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DENMARK; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

EID: 42049116747     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1910     Document Type: Article

References (23)

1. Ganz T 2003 Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:710-720
2. Klotman ME, Chang TL 2006 Defensins in innate antiviral immunity. Nat Rev Immunol 6:447-456
3. Raj PA, Dentino AR 2002 Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 206:9-18
4. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444:860-867
5. Van Gaal LF, Mertens IL, De Block CE 2006 Mechanisms linking obesity with cardiovascular disease. Nature 444:875-880
6. Danesh J, Collins R, Appleby P, Peto R 1998 Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477-1482
7. Nassar H, Lavi E, Akkawi S, Bdeir K, Heyman SN, Raghunath PN, Tomaszewski J, Higazi AA 2007 α-Defensin: link between inflammation and atherosclerosis. Atherosclerosis 194:452-457
8. Higazi AA, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Rader DJ, Usher DC, Kane W, Ganz T, Cines DB 1997 Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 89:4290-4298
9. Bdeir K, Cane W, Canziani G, Chaiken I, Weisel J, Koschinsky ML, Lawn RM, Bannerman PG, Sachais BS, Kuo A, Hancock MA, Tomaszewski J, Raghunath PN, Ganz T, Higazi AA-R, Cines DB 1999 Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94:2007-2019
10. Higazi AA, Barghouti II, Abu-Much R 1995 Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin. J Biol Chem 270:9472-9477
11. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T 1993 Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med 122:202-207
12. Ashitani J, Mukae H, Hiratsuka T, Nakazato M, Kumamoto K, Matsukura S 2002 Elevated levels of α-defensins in plasma and BAL fluid of patients with active pulmonary tuberculosis. Chest 121:519-526
13. Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, Tondolo V, Calvani M, Ricart W, Castagneto M, Mingrone G 2007 Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 92:483-490
14. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis HP, Parving HH 2005 Improved prognosis in type 1diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250-1257
15. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH 2006 Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29:334-339
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470
17. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH 1995 Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489-494
18. Rabkin R, Ryan MP, Duckworth WC 1987 The renal metabolism of insulin. Diabetologia 27:351-357
19. Feld S, Hirschberg R 1996 Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423-480
20. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD 1999 Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351-357
21. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A 2004 Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53:1570-1576
22. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G 2005 Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22:999-1004
23. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C 2005 Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489-3493